House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Haematology

Non-Hodgkin lymphoma: diagnosis and management

NICE · 2016 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG52 organizes non-Hodgkin lymphoma diagnosis, staging and treatment by histology, stage, symptoms and treatment fitness. The reviewed page combines its original clinical recommendations with subsequently linked technology appraisals. This summary highlights diagnostic choices, selected subtype-specific treatment decisions and follow-up; individual appraisal conditions remain necessary when choosing newer drugs.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Secure adequate tissue and use staging tests purposefully

  • Consider excision biopsy first for suspected lymphoma. If surgical risk outweighs benefit, consider a large-calibre core biopsy with as many cores as possible; an inconclusive core should be followed by feasible excision rather than another core. Preserve tissue for further analysis. [1]
  • Consider MYC FISH testing in newly presenting high-grade B-cell lymphoma. If rearranged, test the immunoglobulin partner and BCL2/BCL6; interpret findings with age and IPI, and explain their prognostic implications. [1]
  • Offer staging FDG-PET-CT for clinically and CT-defined stage 1 DLBCL, stage 1 or localized stage 2 follicular lymphoma that could fit a radiotherapy field, and stage 1–2 Burkitt lymphoma with other low-risk features. For other presentations, consider it if results would change management. [1]
  • Do not routinely use interim FDG-PET-CT during DLBCL treatment. Offer it at planned treatment completion for DLBCL or Burkitt lymphoma; for other subtypes, use end-treatment imaging only when it would change management. Consider pre-autologous-transplant PET-CT in high-grade lymphoma. [1]

Separate localized disease from systemic treatment needs

  • Offer local radiotherapy for localized stage 2A follicular lymphoma. If a single radiotherapy volume is unsuitable and the person is asymptomatic, consider observation; if symptomatic and radiotherapy is unsuitable, use the advanced symptomatic disease pathway. [1]
  • Offer rituximab induction for asymptomatic advanced stage 3–4 follicular lymphoma. For untreated symptomatic advanced disease, rituximab–chemotherapy is an option; maintenance rituximab is an option after response to that induction. These options retain the conditions of the cited appraisals. [1]
  • For follicular lymphoma in second or later complete or partial remission, offer autologous-transplant consolidation when no prior transplant has been given and the person is fit. Do not offer high-dose transplant consolidation for concurrent follicular lymphoma and DLBCL responding to first-line treatment. [1]
  • For H. pylori-positive gastric MALT lymphoma, offer eradication treatment, with no concurrent therapy in localized disease; consider eradication even if H. pylori-negative. After clinical and endoscopic response, residual biopsy disease may be observed unless high-risk features are present. [1]
  • For progressive gastric MALT, offer rituximab–chemotherapy or gastric radiotherapy. Disseminated gastric MALT requiring treatment warrants rituximab–chemotherapy; observation is an option only when asymptomatic and without threatened vital-organ function. [1]
  • For non-gastric MALT, consider site, organ risk, extent, treatment morbidity and fitness. Consider radiotherapy for localized sites, and use rituximab–chemotherapy when radiotherapy is unsuitable or disseminated disease requires treatment. [1]

Match mantle-cell treatment intensity to fitness and disease activity

  • Offer rituximab–chemotherapy for symptomatic advanced mantle-cell lymphoma, tailoring intensity to fitness; consider cytarabine-containing treatment in those fit for intensity. Consider radiotherapy for localized stage 1–2 disease and observation for clinically non-progressive, asymptomatic disease when radiotherapy is unsuitable. [1]
  • Consider autologous transplantation for chemosensitive mantle-cell lymphoma when fit. The maintenance schedules differ: consider rituximab every 2 months until progression after R-CHOP response when high-dose therapy is unsuitable, or every 2 months for 3 years in remission after cytarabine-based induction and high-dose chemotherapy. [1]

Use DLBCL-specific risk and treatment pathways

  • For untreated adult DLBCL with IPI 2–5, polatuzumab with rituximab, cyclophosphamide, doxorubicin and prednisolone is an appraisal-linked option. Consider 30 Gy consolidation radiotherapy to initially bulky sites after response in advanced disease, balancing late effects against salvage-treatment risk. [1]
  • For DLBCL, offer CNS prophylaxis when testis, breast, adrenal or kidney is involved, or with 4–5 listed risk factors; consider it with 2–3. Those factors are elevated LDH, age over 60, ECOG at least 2, more than 1 extranodal site, and stage 3–4 disease. [1]
  • The reviewed page lists glofitamab with gemcitabine–oxaliplatin for relapsed or refractory adult DLBCL after exactly 1 prior line when autologous transplant is unsuitable. Lisocabtagene is an option for transplant-suitable adults refractory to or relapsing within 12 months of first-line chemoimmunotherapy, under its appraisal conditions. [1]
  • Offer intensive salvage immunochemotherapy to fit people with relapsed or refractory DLBCL, explaining its transplant-consolidation aim and benefit even without transplantation. Offer autologous consolidation when disease is chemosensitive and the person is fit; consider allogeneic consolidation after autologous relapse or when harvesting is impossible. [1]

Keep histology-specific management and survivorship needs explicit

  • Offer intensive immunochemotherapy for Burkitt lymphoma when fitness permits and less intensive treatment when it does not. In low-risk Burkitt disease, consider DA-EPOCH-R with IV methotrexate, intrathecal methotrexate or both; this summary does not supply complete regimen prescriptions. [1]
  • Consider CHOP first for peripheral T-cell lymphoma and autologous consolidation for chemosensitive disease when fit. For previously treated adult Waldenstrom’s macroglobulinaemia, the linked zanubrutinib option requires bendamustine–rituximab also to be suitable. [1]
  • After complete remission from curative first-line DLBCL treatment, offer clinical follow-up and urgent access for recurrent or new suspicious symptoms. Consider ending relapse-focused regular review after 3 years of continuing remission; do not use LDH or routine imaging for relapse surveillance in asymptomatic people. [1]
  • Explain observation and address anxiety, including transformation risk in low-grade disease. Provide a named key worker, specialist contact details, an end-treatment summary and education about relapse and late effects; discuss exercise and lifestyle from diagnosis onward. [1]

Limitations and use

  • Selected recommendations are summarized, not every drug, transplant-conditioning option or technology-appraisal eligibility condition. Drug doses and complete chemotherapy protocols are not supplied. The reviewed page includes historical clinical recommendations alongside newer appraisal links; listed options are not an independently verified universal treatment hierarchy. CNS prophylaxis recommendations here do not specify a route, dose or regimen.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Non-Hodgkin lymphoma: diagnosis and management

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
20 July 2016
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Secure adequate tissue and use staging tests purposefully
  • Separate localized disease from systemic treatment needs
  • Match mantle-cell treatment intensity to fitness and disease activity
  • Use DLBCL-specific risk and treatment pathways
  • Keep histology-specific management and survivorship needs explicit
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House